The present invention relates to a pharmaceutical composition for preventing or treating cancer comprising an antiviral agent and an antidepressant as an active ingredient and to which a biguanide-based compound can be added, and more specifically, efavirenz, etravirine, rilpivirine, lopinavir, atazanavir, darunavir, and ritonavir as an antiviral agent, and fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, amitriptyline, clomipramine, nortriptyline, desipramine, amoxapine, maprotilline, trimipramine, protriptyline, and melithracene as an antidepressant, in complex, mixture, or combination administration, or efavirenz and fluoxetine with metformin, a biguanide compound, in complex, mixture, or combination administration, shows the significant synergistic anti-cancer activity than when each was administered alone, and so, finally the antiviral agent and antidepressant according to the present invention can be effectively used as an active ingredient in a composition for preventing or treating cancer.

The present invention relates to a pharmaceutical composition for preventing or treating cancer comprising an antiviral agent and an antidepressant as an active ingredient and to which a biguanide-based compound can be added, and more specifically, efavirenz, etravirine, rilpivirine, lopinavir, atazanavir, darunavir, and ritonavir as an antiviral agent, and fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, amitriptyline, clomipramine, nortriptyline, desipramine, amoxapine, maprotilline, trimipramine, protriptyline, and melithracene as an antidepressant, in complex, mixture, or combination administration, or efavirenz and fluoxetine with metformin, a biguanide compound, in complex, mixture, or combination administration, shows the significant synergistic anti-cancer activity than when each was administered alone, and so, finally the antiviral agent and antidepressant according to the present invention can be effectively used as an active ingredient in a composition for preventing or treating cancer.

The present invention concerns materials and methods for treating an ocular Demodex mite infestation of an eye of a human or animal subject, or for treating a condition of the eye or skin associated with ocular Demodex mite infestation, the method comprising topically administering a composition comprising one or more spinosyn compounds to the ocular surface (conjunctiva and/or cornea) or other anatomical structure of the eye, or to an area adjacent the eye.

The present invention concerns materials and methods for treating an ocular Demodex mite infestation of an eye of a human or animal subject, or for treating a condition of the eye or skin associated with ocular Demodex mite infestation, the method comprising topically administering a composition comprising one or more spinosyn compounds to the ocular surface (conjunctiva and/or cornea) or other anatomical structure of the eye, or to an area adjacent the eye.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

The present invention relates to administration or application of a crosslink inducing agent to a subject following a stiffening procedure to the respiratory system. The present invention has identified that such application or administration of a crosslinking reagent to fibrotic tissue allows for improved stability and strength of the tissue.

The present invention relates to administration or application of a crosslink inducing agent to a subject following a stiffening procedure to the respiratory system. The present invention has identified that such application or administration of a crosslinking reagent to fibrotic tissue allows for improved stability and strength of the tissue.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.